Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWOE62)

Drug Name

U3-1565 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proheparin-binding EGF-like growth factor (HBEGF)	TT15SL0	HBEGF_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Proheparin-binding EGF-like growth factor (HBEGF)	DTT	HBEGF	4.07	4.248	3.644	5.044

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proheparin-binding EGF-like growth factor (HBEGF)	DTT	HBEGF	3.92E-01	0.06	0.12

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01290471) Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors. U.S. National Institutes of Health.
2	J Clin Oncol 31, 2013 (suppl; abstr 2519).